H-Index & Metrics Best Publications

H-Index & Metrics

Discipline name H-index Citations Publications World Ranking National Ranking
Medicine D-index 147 Citations 91,258 1,257 World Ranking 486 National Ranking 4

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Cancer
  • Surgery

His primary scientific interests are in Internal medicine, Multiple myeloma, Surgery, Oncology and Gastroenterology. His Chemotherapy, Survival rate, Hazard ratio, Hematology and Macroglobulinemia investigations are all subjects of Internal medicine research. Meletios A. Dimopoulos has included themes like Transplantation and Dexamethasone in his Multiple myeloma study.

His research in Surgery intersects with topics in Adverse effect, Immunopathology and Urology. His research investigates the connection between Oncology and topics such as Immunology that intersect with problems in Disease. His research integrates issues of Endocrinology, Bone resorption, Neutropenia, Hematologic Response and Myeloma protein in his study of Gastroenterology.

His most cited work include:

  • International uniform response criteria for multiple myeloma (2049 citations)
  • International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. (1706 citations)
  • Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group (1627 citations)

What are the main themes of his work throughout his whole career to date?

His scientific interests lie mostly in Internal medicine, Multiple myeloma, Oncology, Surgery and Bortezomib. His study brings together the fields of Gastroenterology and Internal medicine. In general Multiple myeloma study, his work on Melphalan often relates to the realm of In patient, thereby connecting several areas of interest.

His Oncology study integrates concerns from other disciplines, such as Cancer, Clinical trial, Carfilzomib, Immunology and Daratumumab. His studies examine the connections between Surgery and genetics, as well as such issues in Urology, with regards to Renal function. Meletios A. Dimopoulos interconnects Proteasome inhibitor and Pharmacology in the investigation of issues within Bortezomib.

He most often published in these fields:

  • Internal medicine (67.68%)
  • Multiple myeloma (48.61%)
  • Oncology (33.71%)

What were the highlights of his more recent work (between 2017-2021)?

  • Internal medicine (67.68%)
  • Multiple myeloma (48.61%)
  • Oncology (33.71%)

In recent papers he was focusing on the following fields of study:

Meletios A. Dimopoulos focuses on Internal medicine, Multiple myeloma, Oncology, Dexamethasone and Bortezomib. Meletios A. Dimopoulos regularly ties together related areas like Gastroenterology in his Internal medicine studies. As a part of the same scientific study, Meletios A. Dimopoulos usually deals with the Multiple myeloma, concentrating on Clinical trial and frequently concerns with Intensive care medicine and Randomized controlled trial.

His Oncology study combines topics from a wide range of disciplines, such as Ixazomib, Adverse effect, Phases of clinical research and Hazard ratio. His studies in Dexamethasone integrate themes in fields like Monoclonal antibody and Subgroup analysis. His Bortezomib study also includes fields such as

  • Melphalan which connect with Prednisone,
  • Cancer research and related Bone marrow.

Between 2017 and 2021, his most popular works were:

  • Hematological findings and complications of COVID-19. (540 citations)
  • Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma. (191 citations)
  • Oral selinexor-dexamethasone for triple-class refractory multiple myeloma (149 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Cancer
  • Disease

His primary areas of investigation include Internal medicine, Multiple myeloma, Oncology, Dexamethasone and Bortezomib. His research on Internal medicine often connects related topics like Gastroenterology. He performs multidisciplinary studies into Multiple myeloma and In patient in his work.

The various areas that Meletios A. Dimopoulos examines in his Oncology study include Survival rate, Relapsed refractory, Risk stratification and Lymphoma. His study in Dexamethasone is interdisciplinary in nature, drawing from both Refractory, Phases of clinical research and Renal function. His Bortezomib research integrates issues from Proteasome inhibitor and Pharmacology.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

International uniform response criteria for multiple myeloma

B. G. M. Durie;J.-L. Harousseau;J. S. Miguel;J. Blade.
Leukemia (2006)

2975 Citations

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

S. Vincent Rajkumar;Meletios A. Dimopoulos;Antonio Palumbo;Joan Blade.
Lancet Oncology (2014)

2775 Citations

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

Robert A. Kyle;J. Anthony Child;Kenneth Anderson;Bart Barlogie.
British Journal of Haematology (2003)

2665 Citations

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

Jesús F. San Miguel;Rudolf Schlag;Nuriet K. Khuageva;Meletios A. Dimopoulos.
The New England Journal of Medicine (2008)

2229 Citations

Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma

Meletios Dimopoulos;Andrew Spencer;Michael Attal;H. Miles Prince.
The New England Journal of Medicine (2007)

1802 Citations

Osteonecrosis of the Jaw in Cancer After Treatment With Bisphosphonates: Incidence and Risk Factors

Aristotle Bamias;Efstathios Kastritis;Christina Bamia;Lia A. Moulopoulos.
Journal of Clinical Oncology (2005)

1438 Citations

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

James R. Berenson;Alan Lichtenstein;Lester Porter;Meletios A. Dimopoulos.
The New England Journal of Medicine (1996)

1360 Citations

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

Abstr Act;Sagar Lonial;Meletios Dimopoulos;Antonio Palumbo.
The New England Journal of Medicine (2015)

1148 Citations

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

Shaji Kumar;Bruno Paiva;Kenneth C. Anderson;Brian Durie.
Lancet Oncology (2016)

1131 Citations

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

Meletios A. Dimopoulos;Albert Oriol;Hareth Nahi;Jesus San-Miguel.
The New England Journal of Medicine (2016)

1081 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Meletios A. Dimopoulos

Shaji Kumar

Shaji Kumar

Mayo Clinic

Publications: 419

Morie A. Gertz

Morie A. Gertz

Mayo Clinic

Publications: 406

Angela Dispenzieri

Angela Dispenzieri

Mayo Clinic

Publications: 383

S. Vincent Rajkumar

S. Vincent Rajkumar

Mayo Clinic

Publications: 332

Robert A. Kyle

Robert A. Kyle

Mayo Clinic

Publications: 326

Kenneth C. Anderson

Kenneth C. Anderson

Harvard University

Publications: 318

Paul G. Richardson

Paul G. Richardson

Harvard University

Publications: 293

Martha Q. Lacy

Martha Q. Lacy

Mayo Clinic

Publications: 268

Francis K. Buadi

Francis K. Buadi

Mayo Clinic

Publications: 241

David Dingli

David Dingli

Mayo Clinic

Publications: 212

Antonio Palumbo

Antonio Palumbo

University of Turin

Publications: 210

Suzanne R. Hayman

Suzanne R. Hayman

Mayo Clinic

Publications: 205

Nelson Leung

Nelson Leung

Mayo Clinic

Publications: 205

Philippe Moreau

Philippe Moreau

University of Nantes

Publications: 201

Nikhil C. Munshi

Nikhil C. Munshi

Harvard University

Publications: 197

Ola Landgren

Ola Landgren

University of Miami

Publications: 193

Something went wrong. Please try again later.